EN DE
STOCK COMPARISON

NeoPharm CO. vs AUX: Fair Value & Quality

Both stocks run through our valuation models. Here is how NeoPharm CO. (092730) and AUX (AUX) compare, as of Sep 14, 2026.

As of Sep 14, 2026, Fair Value Calculator sees NeoPharm CO. as the more attractively valued of the two: NeoPharm CO. trades at KRW 21,600 versus a fair value of KRW 35,793 (+66%), while AUX trades at PLN 1.18 versus PLN 0.39 (-67%).
NeoPharm CO.
092730.KQ · KRW · Consumer Staples
+66%
upside to fair value
undervalued
PriceKRW 21,600
Fair ValueKRW 35,793
Quality67/100
AUX
AUX.WAR · PLN · Consumer Staples
-67%
upside to fair value
overvalued
PricePLN 1.18
Fair ValuePLN 0.39
Quality57/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

NeoPharm CO.AUX
Valuation
P/E (TTM)4.8×
P/B0.45×
+65.7%Fair value upside−66.9%
3.5%Dividend yield0.2%
Profitability
25%Operating margin0%
0.81×EBIT margin trend (5Y)1.26×
9%Return on assets0%
Growth
-3%Revenue growth (YoY)0%
15.8%Avg. growth/yr (3Y)-4.5%
10.1%Avg. growth/yr (5Y)-9.5%
−1.7%Value creation/yr−28.1%
Balance & size
729.9×Interest coverage (EBIT/interest)8.8×
$210MMarket cap$5M
mixedGrowth qualityweak

NeoPharm CO. leads: 9 to 1 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

NeoPharm CO.of which business quality 67 · market factors 65 AUXof which business quality 51 · market factors 14
ProfitabilityMargins and returns on capital today
66
20
Quality GrowthAre margins and returns improving?
59
47
CashflowEarnings quality: real cash, not paper profit
74
50
Fin. StrengthBalance sheet, leverage, solvency risk
88
39
InvestmentDisciplined investing over empire-building
62
96
Low VolatilityCalm price path (market factor)
49
0
MomentumPrice trend over the last 3–12 months (market factor)
72
30
52W MomentumDistance to the 52-week high (market factor)
71
4
Net IssuanceShare count: buybacks or dilution?
40
82

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyNeoPharm CO.Price KRW 21,600AUXPrice PLN 1.18
DCF Models+98%above the priceKRW 42,724-68%below the pricePLN 0.38
Earnings-Based+9%close to the priceKRW 23,480-81%below the pricePLN 0.23
Multiples+35%above the priceKRW 29,247-64%below the pricePLN 0.43
Asset-Based-61%below the priceKRW 8,368-60%below the pricePLN 0.47
Growth DCF+62%above the priceKRW 35,001-73%below the pricePLN 0.32
Economic Profit-5%close to the priceKRW 20,625-69%below the pricePLN 0.36
Growth Earnings+66%above the priceKRW 35,793-75%below the pricePLN 0.29
Minimum-61%below the priceKRW 8,368-81%below the pricePLN 0.23
Maximum+98%above the priceKRW 42,724-60%below the pricePLN 0.47
Median+35%above the priceKRW 29,247-69%below the pricePLN 0.36
Geometric mean+16%above the priceKRW 25,138-71%below the pricePLN 0.34

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

NeoPharm CO.: 5 of 24 models see the stock below the current price.

AUX: 22 of 22 models see the stock below the current price.

Scenario ranges

From our cautious bear scenario to the optimistic bull scenario. The white tick is the current price (value above it), the green tick the fair value (value below it): if the price sits left of the fair value, there is room to rise.

NeoPharm CO.
Price KRW 21,600
Fair Value KRW 35,793
Bear KRW 22,498Bull KRW 46,530
AUX
Price PLN 1.18
Fair Value PLN 0.39
Bear PLN 0.29Bull PLN 0.48

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

NeoPharm CO. · Consumer Staples

Quality score67 · Top 25%
Fair value upside+66% · Top 25%

AUX · Consumer Staples

Quality score57 · above median
Fair value upside-67% · bottom 25%

Bottom line

As of Sep 14, 2026, Fair Value Calculator sees NeoPharm CO. as the more attractively valued of the two: NeoPharm CO. trades at KRW 21,600 versus a fair value of KRW 35,793 (+66%), while AUX trades at PLN 1.18 versus PLN 0.39 (-67%).

NeoPharm CO. has the higher quality score (67/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.